In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation (2019), MDL No. 2875 (D.N.J.), centralized in the District of New Jersey on February 14, 2019, consolidates more than 1,400 federal cases arising from the FDA's July 13, 2018, announcement that valsartan-containing blood pressure medications were contaminated with N-Nitrosodimethylamine (NDMA), a probable human carcinogen. A related mass-tort comparator appears in the Roundup litigation.
This article examines the contamination record, the MDL's claim structure, the certification and bellwether rulings shaping case value, and the settlement posture as economic-loss claims move toward final approval while personal-injury claims continue.
How NDMA Contamination Triggered the Valsartan Recalls
The factual record begins with the FDA investigation and expands into the manufacturing changes plaintiffs say introduced nitrosamine impurities into the valsartan supply chain. That sequence matters because the MDL's manufacturing-defect theories depend on a traceable contamination pathway rather than a warning-only theory.
The FDA's valsartan investigation traces to a customer complaint that ZHP received on June 6, 2018, after an unknown peak appeared during residual-solvents testing of its valsartan active pharmaceutical ingredient. That peak was identified as the probable human carcinogen N-Nitrosodimethylamine (NDMA). The FDA announced voluntary recalls of valsartan-containing medicines on July 13, 2018.
Three nitrosamine impurities were ultimately identified across recalled products:
- NDMA (N-Nitrosodimethylamine): Classified as a probable human carcinogen under EPA IRIS (Group B2); the FDA set an acceptable daily intake limit of 96 ng/day
- NDEA (N-Nitrosodiethylamine): Also a probable human carcinogen; the FDA set an acceptable daily intake limit of 26.5 ng/day
- NMBA (N-Nitroso-N-methyl-4-aminobutyric acid): Classified as a potential human carcinogen, discovered as the third nitrosamine impurity in ARB medicines in March 2019
The alleged root cause centers on API manufacturing-process changes at ZHP. By 2012, ZHP had adopted a process whose solvent system promoted dimethylamine formation that reacted with nitrite to form NDMA. The FDA's warning letter to ZHP documented these cGMP failures, including the firm's failure to evaluate the potential for mutagenic impurities to form.
Beyond ZHP, recalls expanded to finished-dose products using API from Hetero Labs, Aurobindo, Mylan, Torrent, and Teva. The FDA's laboratory analysis confirmed contamination levels across multiple manufacturers and product lots, and indicated contamination may have persisted for up to four years before the July 2018 recall.
Inside the Valsartan MDL's Claim Tracks
The MDL developed into a multi-track proceeding covering personal injury, consumer economic loss and third-party payor claims. That structure explains why class certification outcomes have mattered as much as bellwether results.
The Judicial Panel on Multidistrict Litigation centralized federal actions on February 14, 2019. The case received docket 1:19-md-02875 in the District of New Jersey.
On December 18, 2019, the JPML expanded the MDL to include losartan and irbesartan actions. The expanded matter is In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation. The litigation proceeds through personal injury claims by plaintiffs alleging cancer or severe liver damage, consumer economic-loss claims by individuals and putative classes alleging overpayment for contaminated products against 40-plus defendants, and third-party payor claims by health care benefit providers seeking reimbursement for payments on contaminated prescriptions.
Hon. Robert B. Kugler presided from centralization through May 2024. Chief Judge Renée Marie Bumb now presides, with Magistrate Judge Sharon A. King and Special Master Hon. Thomas I. Vanaskie (Ret.). The JPML report for May 1, 2026, lists 1,424 actions pending from 1,615 total historical filings.
ZHP Discovery Sanctions
ZHP's litigation conduct has distinguished it from co-defendants. A May 2024 special master order imposed sanctions after ZHP withheld documents and failed to produce its president, Baohua Chen, for deposition.
The sanctions included an adverse-inference instruction that a jury may draw regarding ZHP's knowledge of the contamination and its efforts to prevent disclosure. Chief Judge Bumb later denied ZHP's motion to reverse a related order while granting Teva and Torrent's motion to modify it.
Class Certification and the First Economic-Loss Settlements
No jury verdict has been reached, so the MDL's practical significance comes from rulings defining which claims survive and how they may be valued. Certification decisions and the first settlements have done most of that work.
Daubert and Certification Rulings
The court denied defendants' renewed motion to exclude plaintiffs' general-causation experts in December 2022. On February 8, 2023, in a decision reported at 2023 WL 1818922, the court certified four classes (a consumer economic-loss class, a third-party-payor class, and two medical-monitoring classes), dividing the consumer and TPP classes into 111 state-law subclasses. The opinion tied the contamination to defendants' failure to comply with current good manufacturing practices.
The Third Circuit denied Rule 23(f) interlocutory review of the certification in April 2023, and the court denied decertification on February 26, 2024 (2024 WL 776757).
A March 2024 ruling found a genuine dispute over whether defendants' Orange Book designation of their products as "valsartan" constituted a warranty as to purity, identity, or quality. Package inserts, product labels, and websites that affirmed FDA approval or USP compliance raised additional factual disputes on express warranty claims.
The First Bellwether: Roberts
The first personal-injury bellwether did not reach trial. In Roberts, No. 1:19-md-02875 (D.N.J. Nov. 10, 2025), Chief Judge Bumb granted summary judgment for defendants after excluding the plaintiff's sole specific-causation expert, Dr. Siddiqui, a board-certified hematologist and oncologist. The court found she could not articulate how much NDMA from valsartan is needed to cause hepatocellular carcinoma (HCC), a dose-response gap that rendered her differential diagnosis, in the court's words, "nothing more than speculative ipse dixit."
Pending Economic-Loss Settlements
Economic-loss settlements received preliminary approval on February 2, 2026. The settlements total $15,264,489.80. The agreements allocate $11,365,489.80 to Hetero for valsartan claims, $2,000,000.00 to Aurobindo for irbesartan claims, and $1,899,000.00 to Vivimed for losartan claims.
Personal injury and medical-monitoring claims are excluded. The claim and opt-out deadline passed on June 2, 2026; the final approval hearing is scheduled for June 30, 2026. No settlements exist with ZHP, Teva, or Torrent. The structure mirrors other recall-driven MDLs that resolved economic claims separately from personal-injury claims, as in a comparable device MDL.
What the Litigation Signals for Nitrosamine and Generic-Drug Liability
MDL 2875 now functions as a test case for how nitrosamine claims fit within generic-drug preemption doctrine and post-recall manufacturing scrutiny. The key divide is between claims targeting contamination in production and claims that look like warnings or design challenges.
The FDA's September 2024 Revision 2 guidance expanded manufacturer testing expectations and established new analytical standards for detecting nitrosamine impurities.
Liability questions split along the supply chain. Under PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011), and Mutual Pharmaceutical Co. v. Bartlett, 570 U.S. 472 (2013), failure-to-warn and design-defect claims against generic manufacturers are federally preempted. Manufacturing defect claims survive because federal law does not require a generic manufacturer to introduce NDMA into its product. This asymmetry concentrates exposure at the API-manufacturer level and limits finished-dose manufacturer liability to due diligence failures.
The Roberts exclusion situates valsartan within a broader pattern of pharmaceutical MDLs decided on causation gatekeeping. In the federal Tylenol litigation, exclusion of plaintiffs' general-causation experts ended the consolidated claims, whereas valsartan's general-causation experts survived and the contest narrowed to specific causation.
CMO No. 38 (March 14, 2025) formalized a deficiency process for product-identification gaps in multi-source generic litigation. Under the order, defendants serve notices that identify gaps, plaintiffs have 30 days to cure with documentary evidence, and unresolved disputes move through case management conferences before dismissal motions.
The Wave 2 bellwether schedule identified four cases, all against ZHP, framing the next phase of the personal-injury track much as sequenced bellwethers shaped the 3M earplug MDL before its multibillion-dollar resolution.
Litigation Strategies for Plaintiff and Defense Counsel
The MDL record provides a practical split-screen for both sides. Plaintiffs have a viable general-causation ruling and class certification history to work with, while defendants have a bellwether specific-causation win and product-identification tools that can narrow inventories.
Plaintiff Counsel
CMO 38's 30-day cure window requires plaintiffs to gather pharmacy dispensing records, insurance EOBs, and prescription histories at case intake.
General causation survived Daubert. Specific causation failed in Roberts because the expert could not articulate a dose-response relationship at the plaintiff's exposure level. Screen cases for competing risk factors: cirrhosis, MASH, diabetes, and obesity all create vulnerability to the same exclusion.
The express-warranty theory survived certification and summary judgment, but the court's April 2025 opinion excluded the "zero-value" damages theory. Economic-loss recovery is limited to diminution in value.
Defense Counsel
Defense strategy turns on liability allocation between the API maker and the finished-dose distributor. ZHP's 2012 process change without mutagenicity testing is the documented originating event. Teva obtained partial summary judgment in March 2024, and the opinion states that Torrent and Teva each attested compliance with cGMPs and USP standards.
ZHP's adverse-inference instruction creates structural prejudice risk in any joint trial. Teva and Torrent should move for severance and argue that jurors cannot reliably cabin the adverse inference to the sanctioned party. The court's differential treatment of the co-defendants when it modified the related sanctions order supports separate proceedings.
PI cases involving plaintiffs with multiple independent cancer risk factors carry reduced exposure after the Roberts exclusion. Economic-loss reserves should model diminution-in-value damages.
Practice Implications Across the Nitrosamine Docket
Valsartan litigation demonstrates how a contaminated-generic-drug mass tort proceeds when manufacturing-defect theories survive preemption and causation gatekeeping narrows the personal-injury track. The MDL has produced a class-certification record, a defense bellwether win, and a first round of economic-loss settlements, while most personal-injury claims remain unresolved.
For practitioners, the record rewards early product identification, disciplined causation experts who can address dose-response at the individual level, and reserve modeling calibrated to the Roberts exclusion. Causation gatekeeping has reshaped other pharmaceutical dockets in similar ways, as the paraquat litigation illustrates.
For additional context on another pharmaceutical mass tort, see the Ozempic litigation.
